Payment overview · 2025
General Payments
$571.54
22 reported records · 10 companies
Healthcare provider profile · identity verified
John Manuel Hernandez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MONTEBELLO, CA · NPI 1073683546
Verified facts
What the public records show
CMS Open Payments records show John Manuel Hernandez, MD received $571.54 in general payments during 2025 across 22 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Mounjaro, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $118.49 | 20.7% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $92.16 | 16.1% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $75.11 | 13.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.29 | 12.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $52.24 | 9.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.70 | 8.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.71 | 5.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $28.55 | 5.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $26.96 | 4.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.33 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $529.04 | 21 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $118.49 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $92.16 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $75.11 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $52.24 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.71 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $28.55 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 68 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl | Metformin Hcl | 582 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 448 | 118 |
| Omeprazole | Omeprazole | 445 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 110 |
| Losartan Potassium | Losartan Potassium | 294 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 284 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 77 |
| Gabapentin | Gabapentin | 266 | 65 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 258 | 64 |
| Mirtazapine | Mirtazapine | 251 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 51 |
| Lisinopril | Lisinopril | 209 | 55 |
| Alprazolam | Alprazolam | 198 | 34 |
| Lorazepam | Lorazepam | 191 | 30 |
| Ibuprofen | Ibuprofen | 181 | 54 |
| Donepezil Hcl | Donepezil Hcl | 165 | 41 |
| Carvedilol | Carvedilol | 148 | 23 |
| Temazepam | Temazepam | 133 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 35 |
| Tramadol Hcl | Tramadol Hcl | 122 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 25 |
| Simvastatin | Simvastatin | 115 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 32 |
| Benazepril Hcl | Benazepril Hcl | 105 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 46 |
| Meclizine Hcl | Meclizine Hcl | 102 | 29 |
| Finasteride | Finasteride | 100 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 97 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 28 |
| Glimepiride | Glimepiride | 95 | 24 |
| Januvia | Sitagliptin Phosphate | 95 | 18 |
| Montelukast Sodium | Montelukast Sodium | 94 | 26 |
| Promethazine-Dm | Promethazine/Dextromethorphan | 92 | 45 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 84 | 54 |
| Valsartan | Valsartan | 83 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 18 |
| Furosemide | Furosemide | 81 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 27 |
| Lovastatin | Lovastatin | 72 | 21 |
| Clonidine Hcl | Clonidine Hcl | 70 | 20 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 69 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 16 |
| Eliquis | Apixaban | 68 | 15 |
| Memantine Hcl | Memantine Hcl | 68 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 13 |
| Jardiance | Empagliflozin | 66 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 64 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 23 |
| Trazodone Hcl | Trazodone Hcl | 61 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 18 |
| Aripiprazole | Aripiprazole | 59 | 12 |
| Glipizide | Glipizide | 59 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 18 |
| Alendronate Sodium | Alendronate Sodium | 53 | 16 |
| Methylprednisolone | Methylprednisolone | 53 | 44 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | 12 |
| Ramipril | Ramipril | 51 | 12 |
| Atenolol | Atenolol | 49 | 12 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Spironolactone | Spironolactone | 47 | 18 |
| Primidone | Primidone | 46 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Carisoprodol | Carisoprodol | 41 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Myrbetriq | Mirabegron | 40 | 11 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 13 |
| Hydrocortisone | Hydrocortisone | 38 | 11 |
| Linzess | Linaclotide | 38 | suppressed |
| Kerendia | Finerenone | 37 | suppressed |
| Prednisone | Prednisone | 37 | 17 |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Baclofen | Baclofen | 34 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 33 | 33 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 29 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | 13 |
| Naproxen | Naproxen | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 14 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Benzonatate | Benzonatate | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Mesalamine | Mesalamine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Clonidine | Clonidine | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $571.54 · 22 records | Bayer Healthcare Pharmaceuticals Inc. | AFREZZA, Cologuard Collection Kit, ELIQUIS, EVENITY, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, XIFAXAN, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error